Valeant cuts revenue forecast - 2Q 2017 EarningsRevenue during the quarter fell 8 percent to $2.23-billion in the second quarter ended June 30. This was due to declines in volume and pricing of its generic and neurology products. Net loss narrowed to $38 million from $302 million in prior year period.
Valeant Pharmaceuticals International Earnings AlphaGraphics: Q2 2017 highlights
https://alph.st/b74b2413